Novavax Gets EC Approval for Nuvaxovid Use in Ages 12-17

Dow Jones2022-07-05

Novavax Inc. said Tuesday that the European Commission has approved the expanded conditional marketing authorization of Nuvaxovid NVX-CoV2373 Covid-19 vaccine in the EU for adolescents aged 12 through 17.

The approval follows the positive recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 23.

The authorization was based on data from the ongoing pediatric expansion of a Phase 3 trial of Nuvaxovid in the U.S. Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy at a time when the Delta variant was the predominant strain in the U.S., the company said.

NVX-CoV2373 hasn't been authorized for use in the U.S., and the trade name Nuvaxovid hasn't been approved by the U.S. Food and Drug Administration.

Novavax shares rose 6% to $60.67 after finishing Friday's session up 11%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Kia21
    2022-07-06
    Kia21
    Good
  • AhBart
    2022-07-06
    AhBart
    Well done 👍🏽. More work in the pipeline.....omicron specific and bivalent vaccines will be key 🤟🏻
  • afai123
    2022-07-06
    afai123
    Nice
  • HermioneG
    2022-07-05
    HermioneG
    Awesome!
  • Edwardtoh
    2022-07-05
    Edwardtoh
    Like 
  • Sim1
    2022-07-05
    Sim1
    Like
Leave a comment
10